Uses
JASCAYD is a phosphodiesterase 4 (PDE4) inhibitor indicated for: The treatment of idiopathic pulmonary fibrosis in adult patients. The treatment of progressive pulmonary fibrosis in adult patients.
Source: US FDA prescribing information
- Presentations
- 2
- Brands
- 1
- Manufacturers
- 1
- Available from stock
- 0
Nerandomilast is a prescription medicine indicated for the treatment of idiopathic pulmonary fibrosis in adult patients, among other approved uses. It is available as tablets for oral use. MedsAcross supplies Nerandomilast for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
Key facts
- ATC classification
- L04AA61 Nerandomilast · Immunosuppressive drug, subgroup L04AA
- US FDA first approval
- 7 October 2025
- EU status
- Authorised
- Orphan designation
- Yes
- WHO essential medicine
- Not recorded
- India (CDSCO)
- Not yet confirmed against CDSCO approval lists
- Routes
- Oral
- Dosage forms
- Tablet
- Identifiers
- UNII I5DGT51IB8
Clinical information
From the regulator-approved product information. Each section names its source.
How it works
Nerandomilast is an inhibitor of phosphodiesterase 4 (PDE4) with at least nine-fold preferential inhibition of the PDE4B isoenzyme over PDE4A, PDE4C, and PDE4D based on in vitro data. PDE4 hydrolyzes and inactivates cyclic adenosine monophosphate (cAMP). Nerandomilast exerts both antifibrotic and immunomodulatory effects as PDE4B inhibition elevates intracellular cAMP levels and reduces the expression of profibrotic growth factors and inflammatory cytokines, which are overexpressed in IPF and PPF.
Source: US FDA prescribing information
Dosing overview
Recommended Dosage: 18 mg orally twice daily approximately 12 hours apart with or without food. Reduce JASCAYD to 9 mg twice daily for patients who are unable to tolerate 18 mg twice daily, except in patients taking concomitant moderate CYP3A inducers or pirfenidone. Swallow tablets whole or dispersed in water. See full prescribing information for dosage modification for concomitant use with CYP3A inhibitors and administration instructions for patients who have difficulty swallowing tablets.
Source: US FDA prescribing information
Contraindications
None. None.
Source: US FDA prescribing information
Side effects
Most common adverse reactions (≥5%) are diarrhea, COVID-19, upper respiratory tract infection, depression, weight decreased, decreased appetite, nausea, fatigue, headache, vomiting, back pain, and dizziness.
Source: US FDA prescribing information
Interactions
Strong CYP3A Inhibitors: Reduce JASCAYD dosage to 9 mg twice daily. Strong CYP3A Inducers: Avoid concomitant use with JASCAYD. Moderate CYP3A Inducers: Recommended dosage is 18 mg twice daily. Do not reduce dosage to 9 mg twice daily.
Source: US FDA prescribing information
Storage
Store at 20°C to 25°C (68°F to 77°F), excursions permitted to 15°C to 30°C (59°F to 86°F). Store in the original container to protect from light.
Source: US FDA prescribing information
For healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
All presentations
2 presentations of Nerandomilast, sorted by availability.
| Medicine | Manufacturer | Register | Availability |
|---|---|---|---|
| Jascayd 18 mg tabletOral | Boehringer Ingelheim Pharmaceuticals | US FDA | Available on request |
| Jascayd 9 mg tabletOral | Boehringer Ingelheim Pharmaceuticals | US FDA | Available on request |
Brands by market
1 brand names across 1 markets.
United States
Manufacturers
Regulatory status
Approval facts from US FDA, EMA and CDSCO data, and registration status by country where we hold register data.
Questions and answers
Is Nerandomilast available for export from India?
Yes, on request. MedsAcross lists 2 presentations of Nerandomilast and sources them for licensed hospitals, importers and physicians against valid import documents.
What brand names does Nerandomilast have?
The catalogue lists 1 brand names for Nerandomilast, including Jascayd.
Is Nerandomilast approved by the US FDA?
Yes. The US FDA first approved Nerandomilast on 7 October 2025, according to Drugs@FDA.
Is Nerandomilast authorised in the European Union?
Yes. Nerandomilast has a central EU marketing authorisation (status: authorised), according to European Medicines Agency data.
Does Nerandomilast need cold chain shipping?
No listed presentation of Nerandomilast is recorded as needing a cold chain. Storage conditions are shown on each presentation page.
Which ATC class is Nerandomilast in?
Nerandomilast is classified under ATC code L04AA61 (Nerandomilast).
References
- JASCAYD prescribing information (Boehringer Ingelheim Pharmaceuticals). U.S. National Library of Medicine, DailyMed. Retrieved 14 August 2026
- Jascayd: European public assessment report (EPAR). European Medicines Agency. Retrieved 9 November 2026
Request Nerandomilast for export supply
Tell us the strength, quantity and destination country. Our team replies with availability, lead time and the import documents needed.